# Translational Therapy Shared Resource

> **NIH NIH P30** · UNIVERSITY OF MINNESOTA · 2024 · $71,920

## Abstract

Translational Therapy Shared Resource Summary
Transitioning sophisticated laboratory assays and the manufacturing of biotherapeutic products to the clinic
often represents a significant hurdle for translation of laboratory studies to patient care. The purpose of the
Translational Therapy Shared Resource (TTSR) is to provide state-of-the-art translational research support
services to Masonic Cancer Center (MCC) members to facilitate the monitoring of clinical trials and the
development of novel cellular and immune-based therapies. TTSR works directly with members of the
Scientific Programs at the preclinical, clinical, and laboratory levels, with the goal of developing clinical trials to
test novel therapies. It does this through the following specific aims: 1) To provide immune monitoring and
biorepository management for clinical studies and trials, 2) To provide a cGMP-compliant facility to
manufacture therapeutic biological products, and 3) To develop novel cellular and immune-based therapies.
TTSR has 2 major components: the Translational Therapy Laboratory (TTL) and Molecular and Cellular
Therapeutics (MCT). TTL provides immune monitoring and biorepository management; it is the central
laboratory that processes research blood samples from patients enrolled in clinical trials. MCT is a cGMP-
compliant production facility. TTSR collaborates with investigators in the Immunology and Transplant and
Cellular Therapy Programs to first procure, select, and manipulate cellular products in the basic or preclinical
research setting and then in large-scale preclinical validation runs leading to the production of these products
in the GMP facility. Once trials begin, TTL processes samples from the trials and provides biologic correlates of
how the products created by the MCT facility are performing. TTSR also collaborates with the Clinical
Informatics Shared Resource and the Cancer Research Translational Initiative to assist investigators in
correlating clinical outcomes with product characteristics and any alterations in host immune function.
Martin Felices, PhD, Associate Professor of Medicine (Immunology Program), and John Wager, MD, Professor
of Pediatrics (Transplant and Cellular Therapy Program [TCT]) co-lead TTSR and are supported by David
McKenna, MD, Medical Director of MCT (TCT), and Rose Wangen, Coordinator of TTL. In fiscal year 2022, 38
people used TTSR, including 33 MCC members.

## Key facts

- **NIH application ID:** 10768166
- **Project number:** 2P30CA077598-26
- **Recipient organization:** UNIVERSITY OF MINNESOTA
- **Principal Investigator:** Martin Felices
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $71,920
- **Award type:** 2
- **Project period:** 1998-06-01 → 2029-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768166

## Citation

> US National Institutes of Health, RePORTER application 10768166, Translational Therapy Shared Resource (2P30CA077598-26). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10768166. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*